












"an impressive set with quality from the top
silk down to the most junior barristers."
Chambers & Partners (Information Technology) 2013
'excellence on IT matters'
Legal 500 (Information Technology) 2010
"Fantastic roster of talent" and recommended for being "very modern, forward-thinking and providing sound commercial advice" as well as offering instructing solicitors "a very broad skill set in the soft IP space."
Chambers & Partners 2017
'Top drawer IP set.'
Legal 500 2010
"8 New Square brims with barristers experienced in fighting fiendishly complex, high-value IT and telecoms disputes."
Chambers & Partners 2014
The clerks are described as "helpful," "generous" and "very good at knowing what you want."
Chambers & Partners (Intellectual Property) 2013
"8 New Square brims with barristers experienced in fighting fiendishly complex, high-value IT and telecoms disputes."
Chambers & Partners (Information Technology) 2014
'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
"8 New Square is undoubtedly one of the leading sets for trade mark and copyright cases within the media and entertainment sphere, so much so that stablemates here frequently find themselves pitted against each other in major cases."
Chambers & Partners (Media & Entertainment) 2014
'An incredibly good set for IP matters'.
Legal 500 2010
"There are great people there at all levels and the clerks are very accommodating."
Chambers & Partners (Intellectual property) 2014
'A number of great IT and telecoms barristers.'
Legal 500 2010
Actavis UK Ltd & Ors v Eli Lilly & Company [2015] EWCA Civ 555 (25 June 2015)
Case Summary | Judgment | 25 June 2015
Richard Meade QC and Isabel Jamal represented the Respondents/Claimants, Actavis, in this declaration of non-infringement (‘DNI’) appeal relating to a patent held by the Appellant/Defendant, Eli Lilly. The Patent concerned the use of pemetrexed disodium in the manufacture of a medicament for use in combination therapy. Actavis sought to use other pemetrexed salts (‘the active ingredients’) in their product. DNIs were sought over the UK, French, Spanish and Italian designations of the Patent.
Floyd LJ dismissed the appeal insofar as it related to direct infringement and allowed the appeal insofar as it related to indirect infringement. On a proper construction the claim only covered pemetrexed disodium (and did not cover the alleged “equivalents” of pemetrexed diacid, ditromethamine or dipotassium) but the claim would cover solutions containing sodium ions and pemetrexed ions with at least a 2:1 ratio. Therefore, although the active ingredients would not directly infringe, where a pharmacist reconstituted or diluted the products in saline there would be a stage when “pemetrexed disodium” was present and used and this would amount to indirect infringement. However, as the active ingredients could also be reconstituted in dextrose, Floyd LJ ordered that the issue of whether there would be indirect infringement if Actavis launched a product for reconstitution or dilution with dextrose should be remitted to the Patents Court.
Issues relating to private international law and the Rome II regulation were dealt with obiter, but the Court of Appeal indicated that Eli Lilly’s appeal was not well founded.
Richard Meade QC and Isabel Jamal were instructed by Bird & Bird LLP.